Literature DB >> 9839824

Continuous blockade of both brachial plexus with ropivacaine in phantom pain: a case report.

Peter Lierz1, Klaus Schroegendorfer, Seung Choi, Peter Felleiter, Hans-Georg Kress.   

Abstract

A 39-year-old patient developed phantom pain after amputation of both upper arms following a burn injury. The pain did not respond to naproxen, morphine, carbamazepine, amitriptyline, calcitonin or transcutaneous electrical nerve stimulation (TENS). At the 39th post-operative day an axillary catheter was placed on the right side, as well as an interscalene catheter on the left. Ropivacaine 0.2% was infused, starting with a rate of 4 ml/h, that was increased to 6 ml/h during the subsequent 6 days. Within 20 min of catheter placement complete pain relief was achieved. The patient did not need any other analgesics and remained painfree for 7 months. Neither motor block, nor any other side effects occurred during the infusion of ropivacaine 0.2%. Thus, the patient not only received analgesia, but also got an effective treatment of established phantom pain. A similar approach with bupivacaine may not have been feasible, because of the possibility of toxic side effects. Ropivacaine is a long-acting local anaesthetic which is less toxic than bupivacaine and has the additional advantage of producing less motor-blockade in the concentration used, so the patient was able to move actively without experiencing any pain.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9839824     DOI: 10.1016/S0304-3959(98)00128-6

Source DB:  PubMed          Journal:  Pain        ISSN: 0304-3959            Impact factor:   6.961


  7 in total

Review 1.  Regional anesthesia for postoperative pain control in children: focus on continuous central and perineural infusions.

Authors:  Giorgio Ivani; Valeria Mossetti
Journal:  Paediatr Drugs       Date:  2008       Impact factor: 3.022

2.  Treating intractable phantom limb pain with ambulatory continuous peripheral nerve blocks: a pilot study.

Authors:  Brian M Ilfeld; Tobias Moeller-Bertram; Steven R Hanling; Kyle Tokarz; Edward R Mariano; Vanessa J Loland; Sarah J Madison; Eliza J Ferguson; Anya C Morgan; Mark S Wallace
Journal:  Pain Med       Date:  2013-03-14       Impact factor: 3.750

Review 3.  Neuropathic pain after brachial plexus avulsion--central and peripheral mechanisms.

Authors:  Manoel Jacobsen Teixeira; Matheus Gomes da S da Paz; Mauro Tupiniquim Bina; Scheila Nogueira Santos; Irina Raicher; Ricardo Galhardoni; Diego Toledo Fernandes; Lin T Yeng; Abrahão F Baptista; Daniel Ciampi de Andrade
Journal:  BMC Neurol       Date:  2015-05-04       Impact factor: 2.474

4.  Treating phantom limb pain: cryoablation of the posterior tibial nerve.

Authors:  Matthew Fiala; Abana Azariah; Jean Woo; Ahmed Kamel Abdel Aal; Alexa Levey
Journal:  Radiol Case Rep       Date:  2022-06-27

5.  Ultrasound-guided bilateral combined inguinal femoral and subgluteal sciatic nerve blocks for simultaneous bilateral below-knee amputations due to bilateral diabetic foot gangrene unresponsive to peripheral arterial angioplasty and bypass surgery in a coagulopathic patient on antiplatelet therapy with a history of percutaneous coronary intervention for ischemic heart disease: A case report.

Authors:  Sung Hye Byun; Jonghoon Lee; Jong Hae Kim
Journal:  Medicine (Baltimore)       Date:  2016-07       Impact factor: 1.889

Review 6.  A review of the management of phantom limb pain: challenges and solutions.

Authors:  Cliff Richardson; Jai Kulkarni
Journal:  J Pain Res       Date:  2017-08-07       Impact factor: 3.133

7.  Ambulatory continuous peripheral nerve blocks to treat postamputation phantom limb pain: a multicenter, randomized, quadruple-masked, placebo-controlled clinical trial.

Authors:  Brian M Ilfeld; Bahareh Khatibi; Kamal Maheshwari; Sarah J Madison; Wael Ali Sakr Esa; Edward R Mariano; Michael L Kent; Steven Hanling; Daniel I Sessler; James C Eisenach; Steven P Cohen; Edward J Mascha; Chao Ma; Jennifer A Padwal; Alparslan Turan
Journal:  Pain       Date:  2021-03-01       Impact factor: 7.926

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.